12:00 AM
Jan 02, 2001
 |  BioCentury  |  Strategy

Inhale acquires a small molecule platform

Late last year, Inhale Therapeutic Systems Inc. lost out to Elan Corp. plc as the two vied to acquire Quadrant Health plc for its pulmonary delivery technology. INHL has come back with a new acquisition, of Bradford Particle Design plc, which it says is strategic, while its erstwhile efforts to buy Quadrant were opportunistic.

Bradford (Bradford, U.K.) develops supercritical fluid processing technology, which can be used to manufacture powdered small molecules and proteins. A supercritical fluid (SCF) is simultaneously a fluid at or above the...

Read the full 421 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >